{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:52:40Z","timestamp":1781243560391,"version":"3.54.1"},"reference-count":103,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Background: Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with cure rates exceeding 80% due to advancements in treatment protocols and supportive care. However, in children with Down syndrome (DS), ALL (DS-ALL) presents distinct genomic and clinical challenges. These include mutations in Janus kinase 2 (JAK2), neuroblastoma RAS viral oncogene homolog (NRAS), and E1A-binding protein p300 (EP300), as well as cytokine receptor-like factor 2 (CRLF2) rearrangements\u2014such as P2RY8-CRLF2 fusion\u2014and intrachromosomal amplification of chromosome 21 (iAMP21). These aberrations are associated with poor prognosis and increased risk of relapse. The objective of this study was to present a unique DS-ALL case with five concurrent high-risk genomic lesions and to contextualize its management in light of existing literature, emphasizing minimal residual disease (MRD)-guided therapy and supportive care. Case Report and Results: We present the case of a three-year-old boy with DS and B-cell ALL (B-ALL), in whom multiple high-risk genomic features co-occurred. Despite these adverse prognostic markers, the patient achieved complete remission following an intensive high-dose induction protocol. We also discuss therapeutic strategies that aim at balancing individualized treatment approaches with optimized supportive care to reduce toxicity and minimize relapse risk. Conclusions: This case underlines the importance of comprehensive molecular diagnostics, serial MRD monitoring, and personalized multidisciplinary care in DS-ALL.<\/jats:p>","DOI":"10.3390\/cimb47090704","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T13:01:13Z","timestamp":1756818073000},"page":"704","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["B-Cell Acute Lymphoblastic Leukemia in a Child with Down Syndrome and High-Risk Genomic Lesions"],"prefix":"10.3390","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9783-149X","authenticated-orcid":false,"given":"Cristina-Crengu\u0163a","family":"Albu","sequence":"first","affiliation":[{"name":"Department of Genetics, Faculty of Dentistry, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Bica","sequence":"additional","affiliation":[{"name":"Department 14, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nan","sequence":"additional","affiliation":[{"name":"Department of Dentistry, Caraiman Multifunctional Medical Complex, 011561 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1541-9870","authenticated-orcid":false,"given":"Lucia","family":"Bubulac","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5965-893X","authenticated-orcid":false,"given":"Claudia Florina","family":"Bogdan-Andreescu","sequence":"additional","affiliation":[{"name":"Department of Speciality Disciplines, \u201cTitu Maiorescu\u201d University, 031593 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionu\u0163 Vlad","family":"\u015eerbanic\u0103","sequence":"additional","affiliation":[{"name":"Doctoral School, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian-Viorel","family":"Poalelungi","sequence":"additional","affiliation":[{"name":"Department 13, Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0085-2081","authenticated-orcid":false,"given":"Emin","family":"Cadar","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, \u201cOvidius\u201d University, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea-Mariana","family":"B\u0103n\u0103\u021beanu","sequence":"additional","affiliation":[{"name":"Department of Speciality Disciplines, \u201cTitu Maiorescu\u201d University, 031593 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7869-7595","authenticated-orcid":false,"given":"Alexandru","family":"Burcea","sequence":"additional","affiliation":[{"name":"Department of Speciality Disciplines, \u201cTitu Maiorescu\u201d University, 031593 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1172\/JCI61203","article-title":"Molecular genetics of B-precursor acute lymphoblastic leukemia","volume":"122","author":"Mullighan","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Mohammadian-Hafshejani, A., Farber, I.M., and Kheiri, S. (2024). Global incidence and mortality of childhood leukemia and its relationship with the Human Development Index. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0304354"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ivanov, A.V., Alecsa, M.S., Popescu, R., Starcea, M.I., Mocanu, A.M., Rusu, C., and Miron, I.C. (2023). Pediatric Acute Lymphoblastic Leukemia Emerging Therapies\u2014From Pathway to Target. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054661"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Aureli, A., Marziani, B., Venditti, A., Sconocchia, T., and Sconocchia, G. (2023). Acute Lymphoblastic Leukemia Immunotherapy Treatment: Now, Next, and Beyond. Cancers, 15.","DOI":"10.20944\/preprints202305.0620.v1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_6","unstructured":"PDQ Pediatric Treatment Editorial Board (2025, June 27). Childhood acute lymphoblastic leukemia treatment (PDQ\u00ae): Health professional version, PDQ Cancer Information Summaries, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK65763\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"414","DOI":"10.6004\/jnccn.2019.0024","article-title":"Acute lymphoblastic leukemia, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Brown","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20406207241257901","DOI":"10.1177\/20406207241257901","article-title":"Down syndrome-associated leukaemias: Current evidence and challenges","volume":"15","author":"Mason","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"ref_9","first-page":"361","article-title":"Genomic and epigenomic insights into acute lymphoblastic leukemia","volume":"28","author":"Roberts","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e39909","DOI":"10.1097\/MD.0000000000039909","article-title":"Prognostic impact of next-generation sequencing on myelodysplastic syndrome: A single-center experience","volume":"103","author":"Kaya","year":"2024","journal-title":"Medicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MPH.0000000000002840","article-title":"Acute Myeloid Leukemia and Next-Generation Sequencing Panels for Diagnosis: A Comprehensive Review","volume":"46","author":"Chaudhary","year":"2024","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies","volume":"125","author":"Orfao","year":"2015","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","article-title":"Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics","volume":"10","author":"Anand","year":"2022","journal-title":"Genes Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chea, M., Rigolot, L., Canali, A., and Vergez, F. (2024). Minimal Residual Disease in Acute Myeloid Leukemia: Old and New Concepts. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042150"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1017\/erm.2021.6","article-title":"Increased risk of leukaemia in children with Down syndrome: A somatic evolutionary view","volume":"23","author":"Hasaart","year":"2021","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.gim.2022.08.029","article-title":"Estimation of the number of people with Down syndrome in Australia and New Zealand","volume":"24","author":"Skladzien","year":"2022","journal-title":"Genet. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.3324\/haematol.2023.283225","article-title":"Down syndrome and leukemia: From basic mechanisms to clinical advances","volume":"108","author":"Baruchel","year":"2023","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Koul, A.M., Ahmad, F., Bhat, A., Aein, Q.-U., Ahmad, A., Reshi, A.A., and Kaul, R.-U.-R. (2023). Unraveling Down Syndrome: From Genetic Anomaly to Artificial Intelligence-Enhanced Diagnosis. Biomedicines, 11.","DOI":"10.3390\/biomedicines11123284"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41572-019-0143-7","article-title":"Down syndrome","volume":"6","author":"Antonarakis","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_20","unstructured":"Akhtar, F., and Bokhari, S.R.A. (2025, June 27). Down Syndrome, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526016\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumors in individuals with Down\u2019s syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet"},{"key":"ref_22","first-page":"e174","article-title":"Pattern of malignant disorders in individuals with Down syndrome","volume":"22","author":"Hasle","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_23","first-page":"185","article-title":"Treatment of acute lymphoblastic leukemia in children with Down syndrome","volume":"10","author":"Freedman","year":"1993","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood-2023-185368","article-title":"Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children\u2019s Oncology Group Study AALL1131","volume":"142","author":"Rodriguez","year":"2023","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1200\/JCO.23.00389","article-title":"Outcomes in Children, Adolescents, and Young Adults with Down Syndrome and ALL: A Report from the Children\u2019s Oncology Group","volume":"42","author":"Rabin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2439","DOI":"10.1002\/bdr2.2439","article-title":"Comorbidities and Healthcare Utilization Among Young Adults With Congenital Heart Defects by Down Syndrome Status\u2014Congenital Heart Survey to Recognize Outcomes, Needs, and Wellbeing, 2016\u20132019","volume":"11","author":"Villamil","year":"2025","journal-title":"Birth Defects Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.37358\/RC.19.5.7164","article-title":"Impact of maternal serum screening in early prenatal diagnosis and management of congenital anomalies","volume":"70","author":"Albu","year":"2019","journal-title":"Rev. Chim."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.hoc.2009.11.009","article-title":"Acute leukemias in children with Down syndrome","volume":"24","author":"Zwaan","year":"2010","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_29","first-page":"e49930","article-title":"A review of acute lymphocytic leukemia (ALL) in the pediatric population: Evaluating current trends and changes in guidelines in the past decade","volume":"15","author":"Ekpa","year":"2023","journal-title":"Cureus"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Aronica, T.S., Carella, M., and Balistreri, C.R. (2024). Different Levels of Therapeutic Strategies to Recover the Microbiome to Prevent\/Delay Acute Lymphoblastic Leukemia (ALL) or Arrest Its Progression in Children. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202403.1126.v1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e27459","DOI":"10.1097\/MD.0000000000027459","article-title":"Outcomes of patients with Down syndrome and acute leukemia: A retrospective observational study","volume":"100","author":"Schmidt","year":"2021","journal-title":"Medicine"},{"key":"ref_32","first-page":"875","article-title":"JAK mutations and pediatric myeloproliferative disorders: Pathogenesis, therapeutic targets, and clinical studies","volume":"24","author":"Loh","year":"2010","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_33","first-page":"89","article-title":"JAK and STAT gene mutations and JAK-STAT pathway activation in lympho- and myeloproliferative neoplasms","volume":"12","author":"Grygier","year":"2021","journal-title":"Hematol. Clin. Pract."},{"key":"ref_34","first-page":"325","article-title":"Targeting JAK\/STAT pathway alterations in high-risk acute lymphoblastic leukemia","volume":"384","author":"Tasian","year":"2014","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Marcuzzi, A., Rimondi, E., Melloni, E., Gonelli, A., Grasso, A.G., Barbi, E., and Maximova, N. (2022). New Applications of JAK\/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib. Pharmaceuticals, 15.","DOI":"10.3390\/ph15030374"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Roberts","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Page, E.C., Heatley, S.L., Rehn, J., Thomas, P.Q., Yeung, D.T., and White, D.L. (2023). Gain of chromosome 21 increases the propensity for P2RY8:CRLF2 acute lymphoblastic leukemia via increased HMGN1 expression. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1177871"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","article-title":"Genomics in acute lymphoblastic leukaemia: Insights and treatment implications","volume":"12","author":"Roberts","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_39","unstructured":"Li, W. (2022). Prognostic and Predictive Biomarkers in Precursor B-cell Acute Lymphoblastic Leukemia. Leukemia, Exon Publications. Chapter 10."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Uniyal, P., Kashyap, V.K., Behl, T., Parashar, D., and Rawat, R. (2025). KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of Immunotherapy. Cancers, 17.","DOI":"10.3390\/cancers17050785"},{"key":"ref_41","first-page":"339","article-title":"Ras pathway mutations: An emerging prognostic marker in paediatric acute lymphoblastic leukaemia?","volume":"23","author":"Irving","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"ref_42","first-page":"643","article-title":"Mutations and outcome in relapsed pediatric acute lymphoblastic leukemia","volume":"118","author":"Hof","year":"2011","journal-title":"Blood"},{"key":"ref_43","first-page":"2543","article-title":"EP300 mutations and epigenetic dysregulation in acute lymphoblastic leukemia","volume":"132","author":"Ramadoss","year":"2018","journal-title":"Blood"},{"key":"ref_44","first-page":"793","article-title":"Epigenetic therapy in pediatric acute lymphoblastic leukemia: A new frontier","volume":"5","author":"Tzoneva","year":"2012","journal-title":"Expert Rev. Hematol."},{"key":"ref_45","first-page":"1347","article-title":"Clinical significance of deletions of chromosome 21 in childhood acute lymphoblastic leukemia","volume":"14","author":"Heerema","year":"2000","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.5581\/1516-8484.20130111","article-title":"Intrachromosomal amplification of chromosome 21 (iAMP21) detected by ETV6\/RUNX1 FISH screening in childhood acute lymphoblastic leukemia: A case report","volume":"35","author":"Garcia","year":"2013","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood.2022019094","article-title":"The genomic landscape of acute lymphoblastic leukemia with intrachromosomal amplification of chromosome 21","volume":"142","author":"Gao","year":"2023","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/leu.2013.317","article-title":"An international study of intrachromosomal amplification of chromosome 21 (iAMP21): Cytogenetic characterization and outcome","volume":"28","author":"Harrison","year":"2014","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Gil, J.V., Avetisyan, G., de las Heras, S., Miralles, A., del Ca\u00f1izo, M., Rico, \u00c1., Valerio, M.E., D\u00edaz, V., Pi\u00f1ero, P., and Orellana, C. (2025). Atypical B-Cell Acute Lymphoblastic Leukemia with iAMP21 in the Context of Constitutional Ring Chromosome 21: A Case Report and Review of the Genetic Insights. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26010357"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1182\/blood-2014-03-562918","article-title":"A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia","volume":"124","author":"Moorman","year":"2014","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1016\/j.htct.2022.09.581","article-title":"Flexibility of fish probes in monitoring iAMP21 acute lymphoblastic leukemia: Study of four Brazilian children","volume":"44","author":"Rocha","year":"2022","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/ajmg.a.62864","article-title":"B-cell acute lymphoblastic leukemia with iAMP21 in a patient with Down syndrome due to a constitutional isodicentric chromosome 21","volume":"188","author":"Verdoni","year":"2022","journal-title":"Am. J. Med. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Li, W. (2022). Measurable residual disease testing in acute leukemia: Technology and clinical significance. Leukemia, Exon Publications. Chapter 5.","DOI":"10.36255\/exon-publications-leukemia-measurable-residual-disease"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 Update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_55","first-page":"349","article-title":"Development of sensitive flow cytometry approaches for minimal residual disease detection in pediatric acute lymphoblastic leukemia","volume":"25","year":"2012","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/leu.2009.252","article-title":"Long-term results of St Jude Total Therapy studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia","volume":"24","author":"Pui","year":"2010","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Inaba, H., and Pui, C.-H. (2021). Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091926"},{"key":"ref_58","first-page":"7","article-title":"Down syndrome and congenital heart disease: Perioperative planning and management","volume":"5","author":"Delany","year":"2021","journal-title":"J. Congenit. Cardiol."},{"key":"ref_59","first-page":"e27529","article-title":"Infectious complications in children with Down syndrome and acute leukemia: A prospective study","volume":"66","author":"Tandonnet","year":"2019","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_60","first-page":"569","article-title":"Cardiac monitoring and management in children with Down syndrome undergoing chemotherapy for leukemia","volume":"31","author":"Stanhope","year":"2021","journal-title":"Cardiol. Young"},{"key":"ref_61","first-page":"2335","article-title":"Down syndrome and acute lymphoblastic leukemia","volume":"116","author":"Maloney","year":"2010","journal-title":"Cancer"},{"key":"ref_62","first-page":"6408","article-title":"JAK inhibitors in pediatric acute leukemias: From biology to clinical advances","volume":"22","author":"Fazio","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_64","first-page":"275","article-title":"Down syndrome-specific pathways in acute leukemia: Novel therapeutic directions","volume":"57","author":"Freedman","year":"2020","journal-title":"Semin. Hematol."},{"key":"ref_65","first-page":"181","article-title":"Multidisciplinary approaches for Down syndrome acute leukemias","volume":"31","author":"Zwaan","year":"2017","journal-title":"Leukemia"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood-2006-09-045963","article-title":"Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia","volume":"109","author":"Malinge","year":"2007","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2008-08-170928","article-title":"Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia","volume":"113","author":"Kearney","year":"2009","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood-2009-08-235408","article-title":"Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: A report from the International BFM Study Group","volume":"115","author":"Hertzberg","year":"2010","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41388-021-02126-4","article-title":"HMGN1 plays a significant role in CRLF2 driven Down syndrome leukemia and provides a potential therapeutic target in this high-risk cohort","volume":"41","author":"Page","year":"2022","journal-title":"Oncogene"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41375-024-02493-3","article-title":"Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia","volume":"39","author":"Balestra","year":"2025","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/leu.2011.86","article-title":"Frequency and prognostic implications of JAK1\u20133 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia","volume":"25","author":"Blink","year":"2011","journal-title":"Leukemia"},{"key":"ref_72","first-page":"11","article-title":"JAK2 in Ph-like B-Acute Lymphoblastic Leukemia","volume":"49","author":"Hurtado","year":"2023","journal-title":"J. Assoc. Genet. Technol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41388-020-01567-7","article-title":"RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia","volume":"40","author":"Koschut","year":"2021","journal-title":"Oncogene"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Peroni, E., Gottardi, M., D\u2019Antona, L., Randi, M.L., Rosato, A., and Coltro, G. (2023). Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases. Int. J. Mol. Sci., 24.","DOI":"10.20944\/preprints202309.1589.v1"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2022000395","article-title":"Leukemogenesis in infants and young children with trisomy 21","volume":"2022","author":"Roberts","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2169\/internalmedicine.0174-22","article-title":"A Pathogenic NRAS c.38G>A (p.G13D) Mutation in RARA Translocation-Negative Acute Promyelocytic-Like Leukemia with Concomitant Myelodysplastic Syndrome","volume":"62","author":"Goto","year":"2023","journal-title":"Intern. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e001345","DOI":"10.1136\/lupus-2024-001345","article-title":"Ras-MAPK pathway in patients with lupus nephritis","volume":"12","author":"Zhang","year":"2025","journal-title":"Lupus Sci. Med."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ekmekciu, I., Zucha, D.M., Christmann, J., Wisser, S., Heuer, V., Sargin, B., Hollerbach, S., Lamberti, C., M\u00fcller, L., and Lugnier, C. (2024). Exploring the molecular profile of localized colon cancer: Insights from the AIO Colopredict Plus registry. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1434791"},{"key":"ref_79","first-page":"186","article-title":"Histiocitosis combinada de tipo Langerhans (Histiocitosis de c\u00e9lulas de Langerhans y enfermedad de Erdheim-Chester) en var\u00f3n de 64 a\u00f1os con mutaciones en BRAF y NRAS: A prop\u00f3sito de un caso","volume":"56","year":"2023","journal-title":"Rev. Esp. Patol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/apa.15153","article-title":"Multiorgan involvement and management in children with Down syndrome","volume":"109","author":"Lagan","year":"2020","journal-title":"Acta Paediatr."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Perrotta, F., Piscopiello, D., Rizzo, D., Iosa, G., Garzya, G., Cal\u00f2, P., and Gemma, D. (2024). Cytomegalovirus Pneumonia in a Patient with Down Syndrome. Medicina, 60.","DOI":"10.3390\/medicina60020242"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Vora, A. (2017). Medical supportive care for treatment-related toxicity in childhood ALL. Childhood Acute Lymphoblastic Leukemia, Springer.","DOI":"10.1007\/978-3-319-39708-5"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.37358\/RC.19.7.7383","article-title":"Early prenatal diagnosis of an extremely rare association of Down syndrome and transposition of the great vessels","volume":"70","author":"Albu","year":"2019","journal-title":"Rev. Chim."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3390\/hematolrep15030051","article-title":"Oral Manifestations: A Warning-Sign in Children with Hematological Disease Acute Lymphocytic Leukemia","volume":"15","author":"Soares","year":"2023","journal-title":"Hematol. Rep."},{"key":"ref_85","first-page":"4","article-title":"Extramedullary symptoms at the initial presentation of acute lymphoblastic leukemia in children","volume":"4","author":"Irfan","year":"2023","journal-title":"Interdiscip. Approaches Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Yang, L., Luo, S., and Ye, P. (2025). Extramedullary Relapse of Acute B-Lymphoblastic Leukemia Leading to Paraplegia in a Child with Down Syndrome. Clin. Lab., 71.","DOI":"10.7754\/Clin.Lab.2024.241052"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.oraloncology.2018.06.001","article-title":"Adverse effects of chemotherapy on the teeth and surrounding tissues of children with cancer: A systematic review with meta-analysis","volume":"83","author":"Busenhart","year":"2018","journal-title":"Oral Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zeng, X., Yang, X., Que, J., Du, Q., Zhang, Q., and Zou, J. (2021). Oral Health, Caries Risk Profiles, and Oral Microbiome of Pediatric Patients with Leukemia Submitted to Chemotherapy. BioMed Res. Int., 2021.","DOI":"10.1155\/2021\/6637503"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Albu, C.-C., Bencze, M.-A., Dragomirescu, A.-O., Suciu, I., T\u0103nase, M., Albu, \u015e.-D., Russu, E.-A., and Ionescu, E. (2023). Folic Acid and Its Role in Oral Health: A Narrative Review. Processes, 11.","DOI":"10.3390\/pr11071994"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Khurana, S., Khalifa, A.R., Rezallah, N.N., Lozanoff, S., and Abdelkarim, A.Z. (2024). Craniofacial and Airway Morphology in Down Syndrome: A Cone Beam Computed Tomography Case Series Evaluation. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133908"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Vergier, V., Collignon, A.M., Gosset, M., and Bonnet, A.L. (2025). Periodontal diseases in Down syndrome during childhood: A scoping review. BMC Oral Health, 25.","DOI":"10.1186\/s12903-025-05540-2"},{"key":"ref_92","first-page":"324","article-title":"The importance of customized biometric correlations in the prevention of growth and development disorders\u2014A determining factor in the social integration of children and adolescents with mental disabilities","volume":"72","author":"Albu","year":"2021","journal-title":"Rev. Cercet. Interv. Soc."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"104845","DOI":"10.1016\/j.amsu.2022.104845","article-title":"Late dental effects in children submitted to chemotherapy: A case report","volume":"84","author":"Bousserouit","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Jod\u0142owska, A., and Postek-Stefa\u0144ska, L. (2023). Tooth Abnormalities and Their Age-Dependent Occurrence in Leukemia Survivors. Cancers, 15.","DOI":"10.3390\/cancers15225420"},{"key":"ref_95","first-page":"48","article-title":"Application of artificial intelligence in dental caries prediction related to diet and oral hygiene","volume":"16","author":"Defta","year":"2024","journal-title":"Rom. J. Oral Rehabil."},{"key":"ref_96","first-page":"356","article-title":"Comparison of antimicrobial activity of two commercial toothpastes","volume":"15","author":"Albu","year":"2023","journal-title":"Rom. J. Oral Rehabil."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Dumitriu, A.S., P\u0103unic\u0103, S., Nicolae, X.A., Bodnar, D.C., Albu, \u0218.D., Suciu, I., Ciongaru, D.N., and Giurgiu, M.C. (2023). The effectiveness of the association of chlorhexidine with mechanical treatment of peri-implant mucositis. Healthcare, 11.","DOI":"10.3390\/healthcare11131918"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e700","DOI":"10.1016\/S2352-3026(21)00272-6","article-title":"Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: A matched cohort study","volume":"8","author":"Michels","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/MPH.0000000000002794","article-title":"Six Years of Disease-free Survival After a Second Cord Blood Transplantation for Recurrent Acute Lymphocytic Leukemia in a Child With Down Syndrome","volume":"46","author":"Aoshima","year":"2024","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12185-024-03890-1","article-title":"Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia","volume":"121","author":"Kohso","year":"2025","journal-title":"Int. J. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Papakonstantinou, E., Tragiannidis, A., Ampatzidou, M., Katzilakis, N., Nikita, M., Totikidis, G., Athanasiadou, K.I., Antari, V., Kelaidi, C., and Pelagiadis, I. (2025). Acute Leukemia in Children with Down Syndrome: A Report from the Hellenic HESPHO Group. Hemato, 6.","DOI":"10.3390\/hemato6020008"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e21015","DOI":"10.1097\/MD.0000000000021015","article-title":"Treatment outcomes in children with Acute lymphoblastic leukemia with versus without coexisting Down\u2019s syndrome A systematic review and meta-analysis","volume":"99","author":"Liao","year":"2020","journal-title":"Medicine"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e29044","DOI":"10.1002\/pbc.29044","article-title":"Blinatumomab as a successful and safe therapy in Down syndrome patients with relapsed\/refractory b-precursor acute lymphoblastic leukaemia: Case reports and literature review","volume":"68","author":"Sora","year":"2021","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/9\/704\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:36:59Z","timestamp":1760035019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/9\/704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":103,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["cimb47090704"],"URL":"https:\/\/doi.org\/10.3390\/cimb47090704","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}